Emerging Treatment Approaches for COVID-19 Infection: A Critical Review
- PMID: 37070448
- DOI: 10.2174/1566524023666230417112543
Emerging Treatment Approaches for COVID-19 Infection: A Critical Review
Abstract
In the present scenario, the SARS-CoV-2 virus has imposed enormous damage on human survival and the global financial system. It has been estimated that around 111 million people all around the world have been infected, and about 2.47 million people died due to this pandemic. The major symptoms were sneezing, coughing, cold, difficulty breathing, pneumonia, and multi-organ failure associated 1with SARS-CoV-2. Currently, two key problems, namely insufficient attempts to develop drugs against SARSCoV-2 and the lack of any biological regulating process, are mostly responsible for the havoc caused by this virus. Henceforth, developing a few novel drugs is urgently required to cure this pandemic. It has been noticed that the pathogenesis of COVID-19 is caused by two main events: infection and immune deficiency, that occur during the pathological process. Antiviral medication can treat both the virus and the host cells. Therefore, in the present review, the major approaches for the treatment have been divided into "target virus" and "target host" groups. These two mechanisms primarily rely on drug repositioning, novel approaches, and possible targets. Initially, we discussed the traditional drugs per the physicians' recommendations. Moreover, such therapeutics have no potential to fight against COVID-19. After that, detailed investigation and analysis were conducted to find some novel vaccines and monoclonal antibodies and conduct a few clinical trials to check their effectiveness against SARSCoV- 2 and mutant strains. Additionally, this study presents the most successful methods for its treatment, including combinatorial therapy. Nanotechnology was studied to build efficient nanocarriers to overcome the traditional constraints of antiviral and biological therapies.
Keywords: Peptide repurposing; SARS-CoV-2; antiviral medications.; proteomics; therapeutics; transcriptomics.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action.Biochem Pharmacol. 2021 Jan;183:114296. doi: 10.1016/j.bcp.2020.114296. Epub 2020 Oct 22. Biochem Pharmacol. 2021. PMID: 33191206 Free PMC article. Review.
-
Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to.Mol Divers. 2021 Feb;25(1):625-659. doi: 10.1007/s11030-020-10134-x. Epub 2020 Sep 2. Mol Divers. 2021. PMID: 32880078 Free PMC article. Review.
-
Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.SLAS Discov. 2020 Dec;25(10):1097-1107. doi: 10.1177/2472555220945281. Epub 2020 Jul 21. SLAS Discov. 2020. PMID: 32692266 Free PMC article.
-
Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.Curr Pharm Biotechnol. 2021;22(2):192-199. doi: 10.2174/1389201021999200820155927. Curr Pharm Biotechnol. 2021. PMID: 32867651 Review.
-
Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.Mol Cell Biochem. 2021 Feb;476(2):553-574. doi: 10.1007/s11010-020-03924-2. Epub 2020 Oct 7. Mol Cell Biochem. 2021. PMID: 33029696 Free PMC article. Review.
Cited by
-
Assessment of Selected Biochemical Parameters of the Renin-Angiotensin-Aldosterone System in Repeat Convalescent Plasma Donors in the Context of Long-Term Changes Following SARS-CoV-2 Infection.J Clin Med. 2025 Jul 10;14(14):4910. doi: 10.3390/jcm14144910. J Clin Med. 2025. PMID: 40725601 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous